

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



EP/117502

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : G01N 35/00		A2	(11) International Publication Number: WO 00/60361 (43) International Publication Date: 12 October 2000 (12.10.00)
(21) International Application Number: PCT/US00/08111 (22) International Filing Date: 27 March 2000 (27.03.00)		(74) Agents: SEIDMAN, Stephanie, L. et al.; Heller Ehrman White & McAuliffe LLP, Suite 700, 4250 Executive Square, La Jolla, CA 92037 (US).	
(30) Priority Data: 09/285,481 2 April 1999 (02.04.99) US		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-In-Part (CIP) to Earlier Application US 09/285,481 (CON) Filed on 2 April 1999 (02.04.99)			
(71) Applicant (<i>for all designated States except US</i>): SEQUENOM, INC. [US/US]; 11555 Sorrento Valley Road, San Diego, CA 92121 (US).			
(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): KÖSTER, Hubert [DE/US]; 8636-C Via Mallorca Drive, La Jolla, CA 92037 (US). YIP, Ping [US/US]; 3541 Copley Avenue, San Diego, CA 92116 (US). STEADMAN, Jhobe [US/US]; 11743 Aspen View Drive, San Diego, CA 92128 (US). REUTER, Dirk [DE/DE]; Walter-Gropius-Weg 7g, D-22844 Norderstedt (DE). MACDONALD, Richard [CA/US]; 6242 Snowbond Street, San Diego, CA 92120 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: AUTOMATED PROCESS LINES			
(57) Abstract <p>A fully automated modular analytical system integrates instrumentation to permit analysis of biopolymer samples, such as nucleic acids, proteins, peptides and carbohydrates. The system integrates analytical methods of detection and analysis, such as mass spectrometry, radiolabeling, mass tags, chemical tags, fluorescence and chemiluminescence, with robotic technology and automated chemical reaction systems to provide a high-throughput, accurate automated system for high throughput analyses.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

AUTOMATED PROCESS LINES

RELATED APPLICATIONS

Benefit of priority to U.S. application Serial No. 09/285,481 to Hubert Köster, Ping Yip, Jhobe Steadman, Dirk Reuter and Richard MacDonald, filed

5 April 2, 1999, entitled "AUTOMATED PROCESS LINE" is claimed. Where permitted, the subject matter of this application is incorporated by reference in its entirety.

FIELD OF THE INVENTION

Provided herein are systems and methods using the systems for

10 performing high throughput analyses of biopolymers.

BACKGROUND OF THE INVENTION

In recent years, developments in the field of life sciences have proceeded at a breathtaking rate. Ground breaking scientific discoveries and advances in such fields as genomics (sequencing and characterization of genetic information

15 and analysis of the relationship between gene activity and cell function) and proteomics (systematic analysis of protein expression in tissues, cells, and biological systems) promise to reshape the fields of medicine, agriculture, and environmental science. The success of these efforts depends, in part, on the development of sophisticated laboratory tools that will automate and expedite

20 the testing and analysis of biological samples.

Current methods of testing typically employ multiple instruments for preparing and analyzing samples and involve multiple manual handling steps and transfers. Such procedures are labor-intensive, time-consuming, and costly and they are susceptible to human error, sample contamination, and loss. After

25 samples have been prepared, they can be subjected to testing procedures that produce data for analysis. Conventional testing procedures often must be performed by an individual laboratory technician, one sample at a time.

Laboratory technicians are typically individuals who are most likely trained to operate only a single instrument. Automation will reduce the number of

30 personnel and training necessary to carry out the research. Reliable and accurate automated process and analysis tools are necessary for the benefits of recent scientific discoveries to be fully achieved.

Genomic research is increasing the availability of genomic markers that can be used for the identification of all organisms, including humans. These markers (all genetic loci including SNPs, microsatellites and other noncoding genomic regions) provide a way to not only identify populations but also allow 5 stratification of populations according to their response to drug treatment, resistance to environmental agents, and other factors. Importantly, the identification of the large number of genomic markers has become the driving force behind the development of new automated technologies.

At the forefront of the efforts to develop better analytical tools are efforts 10 to expedite the analysis of complex biochemical structures. For example, robotic devices have been employed to assist in sample preparation and handling.

Such automated sample preparation systems could find application in the areas of: identification and validation of disease-causing genes or drug targets; defining mutations and polymorphisms, associated with specific diseases; 15 monitoring gene expression and comparing disease states, cell cycles or other changes; genetic profiling of patients for responsiveness to genomics-based therapies; and genetic profiling of subjects in drug clinical studies to link response with genotype.

The utility of genomic markers to identify and stratify populations is 20 depending on the industry's ability to measure great numbers (100-100,000) of markers in large populations. This approach is extremely limited in terms of time and research costs. Automation of these systems provides advantages such as increasing throughput and accuracy, but miniaturization also is an important consideration in terms of research costs. Accordingly, there is a need to 25 automate processes in which very small volumes are handled, and retain the accuracy of the results to permit their use in high throughput screening protocols and diagnostics.

Therefore it is an object herein to provide automated systems and methods for high-throughput analysis of biological samples, particularly samples 30 of very small volume, for screening, diagnosis and other procedures. Other objects will become apparent from the following disclosure.

SUMMARY OF THE INVENTION

Provided herein is a fully automated modular analytical system that integrates sample preparation, instrumentation, and analysis of biopolymer samples. The samples include, but are not limited to, those containing biopolymers, such as but are not limited to, nucleic acids, proteins, peptides, carbohydrates, PNA (peptide nucleic acids), biopolymer (nucleic acid/peptide) analogs, and libraries of combinatorial molecules. Samples of interest include biological samples, such as but are not limited to, tissue and body fluid samples from humans and other mammals.

10 The system integrates analytical methods of detection and analysis, including but are not limited to, mass spectrometry, radiolabeling, mass tags, chemical tags, fluorescence and chemiluminescence, with robotic technology and automated chemical reaction systems to provide a high-throughput, accurate system called an Automated Process Line (APL). The systems and methods provided herein are particularly suited for handling very small volumes, on the order of milliliters, microliters and submicroliters, nanoliters and even smaller picoliter volumes.

20 In certain embodiments, the analytical system includes one portion that is a contamination-controlled environment, such as a clean room or laminar flow room, and includes a means, such as a transporter, for moving the samples from such environment into a second room or space for further processing. This dual space system permits performance of procedures that require clean room conditions to be automatedly linked to procedures that do not require such conditions. The systems are particularly useful for analysis of nucleic acid and

25 protein samples, such as detection of polymorphisms, particularly single nucleotide polymorphisms, and particularly, using mass spectrometric analyses.

Integrated systems, such as the system exemplified herein and designated an Automated Process Line (APL), for performing a reactions is provided. It includes a process line that has a plurality of processing stations, each of which performs a procedure on a biological sample contained in a reaction vessel; a robotic system that transports the reaction vessel from processing station to processing station; a control system that determines when

the procedure at each processing station is complete and, in response, moves the reaction vessel to the next test station, and continuously processes reaction vessels one after another until the control system receives a stop instruction; and a data analysis system that receives test results of the process line and

5 automatically processes the test results to make a determination regarding the biological sample in the reaction vessel is provided.

The automated system can run unattended continuously with a continuous sample throughput and is capable of analyzing on the order of 10,000-50,000 genotypes per day. The results are highly accurate and

10 reproducible.

Also provided herein are methods for automated analysis of biopolymers using the integrated automated highthroughput system. In preferred embodiments, provided are automated methods for preparing a biological sample for analysis; introducing the sample into an analytical instrument; recording

15 sample data; automatically processing and interpreting the data; and storing the data in a bioinformatics database. In a particular embodiment, patient DNA samples are automatically analyzed to determine genotype.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram of the components of the automated process line.

20 FIG. 2 shows a magnetic strip construction of the magnetic lift illustrated in FIG. 1.

FIG. 3 shows a point-magnet construction of the magnetic lift illustrated in FIG. 1.

FIG. 4 shows the robotic interface between the chip processor and the

25 mass spectrometer of the automated process line illustrated in FIG. 1.

FIG. 5 shows a comparison of a mass spectrum of a test sample with stored spectra from samples with known genotypes.

FIG. 6 is a flow diagram that illustrates the data analysis processing steps performed by the automated process line of FIG. 1.

30 FIG. 7 shows an example of the user interface to the automated high throughput system (the APL automated system).

FIG. 8 shows an example of the interface to a database of experimental mass spectral data.

DETAILED DESCRIPTION AND PREFERRED EMBODIMENTS

Definitions

5 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, patent applications and publications referred to throughout the disclosure, including the background, herein are, unless noted otherwise, incorporated by reference in their entirety. In the event 10 a definition in this section is not consistent with definitions elsewhere, the definition set forth in this section will control.

As used herein, a molecule refers to any molecule or compound that is linked that is analyzed by the methods contemplated herein. For purposes herein, the molecules are often linked to a solid support, such as a bead.

15 Typically such molecules are biological particles or macromolecules or components or precursors thereof, such as peptides, proteins, small organics, oligonucleotides or monomeric units of the peptides, organics, nucleic acids and other macromolecules. A monomeric unit refers to one of the constituents from which the resulting compound is built. Thus, monomeric units include, but are 20 not limited to, nucleotides, amino acids, and pharmacophores from which small organic molecules are synthesized.

As used herein, macromolecule refers to any molecule having a molecular weight from the hundreds up to the millions. Macromolecules include peptides, 25 proteins, nucleotides, nucleic acids, and other such molecules that are generally synthesized by biological organisms, but can be prepared synthetically or using recombinant molecular biology methods.

As used herein, a biological particle refers to a virus, such as a viral vector or viral capsid with or without packaged nucleic acid, phage, including a phage vector or phage capsid, with or without encapsulated nucleotide acid, a 30 single cell, including eukaryotic and prokaryotic cells or fragments thereof, a liposome or micellar agent or other packaging particle, and other such biological materials. For purposes herein, biological particles include molecules that are not

typically considered macromolecules because they are not generally synthesized, but are derived from cells and viruses.

As used herein, the term "nucleic acid" refers to single-stranded and/or double-stranded polynucleotides such as deoxyribonucleic acid (DNA), and

5 ribonucleic acid (RNA) as well as analogs or derivatives of either RNA or DNA. Also included in the term "nucleic acid" are analogs of nucleic acids such as peptide nucleic acid (PNA), phosphorothioate DNA, and other such analogs and derivatives.

As used herein, the term "biological sample" refers to any material

10 obtained from any living source, including but are not limited to animal, particularly mammals, preferably humans, plant, bacterial, fungal, protist viral samples. For purposes herein, the biological sample preferably contains a nucleic acid molecule. Examples of appropriate biological samples include, but are not limited to: solid materials (e.g., tissue, cell pellets, biopsies) and

15 biological fluids (e.g., urine, blood, saliva, amniotic fluid, mouth wash, cerebral spinal fluid and other body fluids).

As used herein, the phrases "chain-elongating nucleotides" and "chain-terminating nucleotides" are used in accordance with their art recognized meaning. For example, for DNA, chain-elongating nucleotides include

20 2'deoxyribonucleotides (e.g., dATP, dCTP, dGTP and dTTP) and chain-terminating nucleotides include 2', 3'-dideoxyribonucleotides (e.g., ddATP, ddCTP, ddGTP, ddTTP). For RNA, chain-elongating nucleotides include ribonucleotides (e.g., ATP, CTP, GTP and UTP) and chain-terminating nucleotides include 3'-deoxyribonucleotides (e.g., 3'dA, 3'dC, 3'dG and 3'dU). A complete

25 set of chain elongating nucleotides refers to dATP, dCTP, dGTP and dTTP. The term "nucleotide" is also well known in the art.

As used herein, nucleotides include nucleoside mono-, di-, and triphosphates. Nucleotides also include modified nucleotides such as phosphorothioate nucleotides and deazapurine nucleotides. A complete set of

30 chain-elongating nucleotides refers to four different nucleotides that can hybridize to each of the four different bases comprising the DNA template.

As used herein, "multiplexing" refers to the simultaneously detection of more than one analyte, such as more than one (mutated) loci on a particular captured nucleic acid fragment (on one spot of an array).

As used herein, the term "biopolymer" is used to mean a biological

- 5 molecule composed of two or more monomeric subunits, or derivatives thereof, which are linked by a bond or a macromolecule. A biopolymer can be, for example, a polynucleotide, a polypeptide, a carbohydrate, or a lipid, or derivatives or combinations thereof, for example, a nucleic acid molecule containing a peptide nucleic acid portion or a glycoprotein, respectively. The
- 10 methods and systems herein, though described with reference to biopolymers, can be adapted for use with other synthetic schemes and assays, such as organic syntheses of pharmaceuticals, or inorganics and any other reaction or assay performed on a solid support or in a well in nanoliter volumes.

As used herein, the term "nucleic acid" refers to single-stranded and/or

- 15 double-stranded polynucleotides such as deoxyribonucleic acid (DNA), and ribonucleic acid (RNA) as well as analogs or derivatives of either RNA or DNA. Also included in the term "nucleic acid" are analogs of nucleic acids such as peptide nucleic acid (PNA), phosphorothioate DNA, and other such analogs and derivatives.

- 20 As used herein, the term "polynucleotide" refers to an oligomer or polymer containing at least two linked nucleotides or nucleotide derivatives, including a deoxyribonucleic acid (DNA), a ribonucleic acid (RNA), and a DNA or RNA derivative containing, for example, a nucleotide analog or a "backbone" bond other than a phosphodiester bond, for example, a phosphotriester bond, a
- 25 phosphoramidate bond, a phosphorothioate bond, a thioester bond, or a peptide bond (peptide nucleic acid). The term "oligonucleotide" also is used herein essentially synonymously with "polynucleotide," although those in the art will recognize that oligonucleotides, for example, PCR primers, generally are less than about fifty to one hundred nucleotides in length.

- 30 Nucleotide analogs contained in a polynucleotide can be, for example, mass modified nucleotides, which allows for mass differentiation of polynucleotides; nucleotides containing a detectable label such as a fluorescent,

radioactive, luminescent or chemiluminescent label, which allows for detection of a polynucleotide; or nucleotides containing a reactive group such as biotin or a thiol group, which facilitates immobilization of a polynucleotide to a solid support. A polynucleotide also can contain one or more backbone bonds that

5 are selectively cleavable, for example, chemically, enzymatically or photolytically. For example, a polynucleotide can include one or more deoxyribonucleotides, followed by one or more ribonucleotides, which can be followed by one or more deoxyribonucleotides, such a sequence being cleavable at the ribonucleotide sequence by base hydrolysis. A polynucleotide also can

10 contain one or more bonds that are relatively resistant to cleavage, for example, a chimeric oligonucleotide primer, which can include nucleotides linked by peptide nucleic acid bonds and at least one nucleotide at the 3' end, which is linked by a phosphodiester bond, or the like, and is capable of being extended by a polymerase. Peptide nucleic acid sequences can be prepared using well known

15 methods (see, for example, Weiler *et al.*, Nucleic acids Res. 25:2792-2799 (1997)).

A polynucleotide can be a portion of a larger nucleic acid molecule, for example, a portion of a gene, which can contain a polymorphic region, or a portion of an extragenic region of a chromosome, for example, a portion of a

20 region of nucleotide repeats such as a short tandem repeat (STR) locus, a variable number of tandem repeats (VNTR) locus, a microsatellite locus or a minisatellite locus. A polynucleotide also can be single stranded or double stranded, including, for example, a DNA-RNA hybrid, or can be triple stranded or four stranded. Where the polynucleotide is double stranded DNA, it can be in an

25 A, B, L or Z configuration, and a single polynucleotide can contain combinations of such configurations.

As used herein, the term "polypeptide," means at least two amino acids, or amino acid derivatives, including mass modified amino acids and amino acid analogs, that are linked by a peptide bond, which can be a modified peptide bond. A polypeptide can be translated from a polynucleotide, which can include at least a portion of a coding sequence, or a portion of a nucleotide sequence that is not naturally translated due, for example, to it being located in a reading

frame other than a coding frame, or it being an intron sequence, a 3' or 5' untranslated sequence, a regulatory sequence such as a promoter, or the like. A polypeptide also can be chemically synthesized and can be modified by chemical or enzymatic methods following translation or chemical synthesis. The terms

5 "polypeptide," "peptide" and "protein" are used essentially synonymously herein, although the skilled artisan will recognize that peptides generally contain fewer than about fifty to one hundred amino acid residues, and that proteins often are obtained from a natural source and can contain, for example, post-translational modifications. A polypeptide can be post-translationally modified by

10 phosphorylation (phosphoproteins), glycosylation (glycoproteins, proteoglycans), and the like, which can be performed in a cell or in a reaction *in vitro*.

As used herein, the term "conjugated" refers stable attachment, preferably ionic or covalent attachment. Among preferred conjugation means are: streptavidin- or avidin- to biotin interaction; hydrophobic interaction; 15 magnetic interaction (*e.g.*, using functionalized magnetic beads, such as DYNABEADS, which are streptavidin-coated magnetic beads sold by Dynal, Inc. Great Neck, NY and Oslo Norway); polar interactions, such as "wetting" associations between two polar surfaces or between oligo/polyethylene glycol; formation of a covalent bond, such as an amide bond, disulfide bond, thioether 20 bond, or via crosslinking agents; and via an acid-labile or photocleavable linker.

As used herein equivalent, when referring to two sequences of nucleic acids means that the two sequences in question encode the same sequence of amino acids or equivalent proteins. When "equivalent" is used in referring to two proteins or peptides, it means that the two proteins or peptides have 25 substantially the same amino acid sequence with only conservative amino acid substitutions that do not substantially alter the activity or function of the protein or peptide. When "equivalent" refers to a property, the property does not need to be present to the same extent [*e.g.*, two peptides can exhibit different rates of the same type of enzymatic activity], but the activities are preferably 30 substantially the same. "Complementary," when referring to two nucleotide sequences, means that the two sequences of nucleotides are capable of hybridizing, preferably with less than 25%, more preferably with less than 15%,

-10-

even more preferably with less than 5%, most preferably with no mismatches between opposed nucleotides. Preferably the two molecules will hybridize under conditions of high stringency.

As used herein: stringency of hybridization in determining percentage

- 5 mismatch are those conditions understood by those of skill in the art and typically are substantially equivalent to the following:
 - 1) high stringency: 0.1 x SSPE, 0.1% SDS, 65°C
 - 2) medium stringency: 0.2 x SSPE, 0.1% SDS, 50°C
 - 3) low stringency: 1.0 x SSPE, 0.1% SDS, 50°C
- 10 It is understood that equivalent stringencies may be achieved using alternative buffers, salts and temperatures.
- 15 As used herein, a primer when set forth in the claims refers to a primer suitable for mass spectrometric methods requiring immobilizing, hybridizing, strand displacement, sequencing mass spectrometry refers to a nucleic acid must be of low enough mass, typically about 70 nucleotides or less than 70, and of sufficient size to be useful in the mass spectrometric methods described herein that rely on mass spectrometric detection. These methods include primers for detection and sequencing of nucleic acids, which require a sufficient number nucleotides to form a stable duplex, typically about 6-30, preferably
- 20 about 10-25, more preferably about 12-20. Thus, for purposes herein a primer will be a sequence of nucleotides comprising about 6-70, more preferably a 12-70, more preferably greater than about 14 to an upper limit of 70, depending upon sequence and application of the primer. The primers herein, for example for mutational analyses, are selected to be upstream of loci useful for diagnosis
- 25 such that when performing using sequencing up to or through the site of interest, the resulting fragment is of a mass that sufficient and not too large to be detected by mass spectrometry. For mass spectrometric methods, mass tags or modifier are preferably included at the 5'-end, and the primer is otherwise unlabeled.

-11-

As used herein, "conditioning" of a nucleic acid refers to modification of the phosphodiester backbone of the nucleic acid molecule (e.g., cation exchange) for the purpose of eliminating peak broadening due to a heterogeneity in the cations bound per nucleotide unit. Contacting a nucleic acid molecule

- 5 with an alkylating agent such as alkyl iodide, iodoacetamide, β -iodoethanol, or 2,3-epoxy-1-propanol, the monothio phosphodiester bonds of a nucleic acid molecule can be transformed into a phosphotriester bond. Likewise, phosphodiester bonds may be transformed to uncharged derivatives employing trialkylsilyl chlorides. Further conditioning involves incorporating nucleotides that
- 10 reduce sensitivity for depurination (fragmentation during MS) e.g., a purine analog such as N7- or N9-deazapurine nucleotides, or RNA building blocks or using oligonucleotide triesters or incorporating phosphorothioate functions that are alkylated or employing oligonucleotide mimetics such as peptide nucleic acid (PNA).
- 15 As used herein, the term "solid support" means a non-gaseous, non-liquid material having a surface. Thus, a solid support can be a flat surface constructed, for example, of glass, silicon, metal, plastic or a composite; or can be in the form of a bead such as a silica gel, a controlled pore glass, a magnetic or cellulose bead; or can be a pin, including an array of pins suitable for
- 20 combinatorial synthesis or analysis.

As used herein, substrate refers to an insoluble support onto which a sample is deposited according to the materials described herein. Sample may be linked directly or via a linker and retained by any suitable means, including covalent, ionic and other bonds and other interactions. Examples of appropriate substrates include solid supports, but are not limited to, silica gel, controlled pore glass, magnetic beads, agarose gels and crosslinked dextroses (i.e., Sepharose and Sephadex), cellulose and other materials known to those of skill in the art, to serve as solid support matrices. For example, substrates may be formed from any or combinations of: silica gel, glass, magnetic materials, polystyrene/1% divinylbenzene resins, such as Wang resins, which are Fmoc-amino acid-4-(hydroxymethyl)phenoxyethylcopoly(styrene-1% divinylbenzene (DVD)) resin, chlorotriyl (2-chlorotriylchloride copoly-

-12-

styrene-DVB resin), Merrifield (chloromethylated copolystyrene-DVB) resin metal, plastic, cellulose, cross-linked dextrans, such as those sold under the trade name Sephadex (Pharmacia) and agarose gel, such as gels sold under the trade name Sepharose (Pharmacia), which is a hydrogen bonded

- 5 polysaccharide-type agarose gel, and other such resins and solid phase supports known to those of skill in the art. The support matrices may be in any shape or form, including, but not limited to: capillaries, flat supports such as glass fiber filters, glass surfaces, metal surfaces (steel, gold, silver, aluminum, copper and silicon), plastic materials including multiwell plates or membranes (e.g., of
- 10 polyethylene, polypropylene, polyamide, polyvinylidenefluoride), pins (e.g., arrays of pins suitable for combinatorial synthesis or analysis or beads in pits of flat surfaces such as wafers (e.g., silicon wafers) with or without plates, and beads. The supports include any supports used for retaining or conjugating macromolecules and biopolymers, and biological particles.
- 15 As used herein, a selectively cleavable linker is a linker that is cleaved under selected conditions, such as a photocleavable linker, a chemically cleavable linker and an enzymatically cleavable linker (i.e., a restriction endonuclease site or a ribonucleotide/RNase digestion). The linker is interposed between the support and immobilized DNA.
- 20 As used herein, the term "liquid dispensing system" means a device that can transfer a predetermined amount of liquid to a target site. The amount of liquid dispensed and the rate at which the liquid dispensing system dispenses the liquid to a target site, which can contain a reaction mixture, can be adjusted manually or automatically, thereby allowing a predetermined volume of the liquid
- 25 to be maintained at the target site.

As used herein, the term "liquid" is used broadly to mean a non-solid, non-gaseous material, which can be homogeneous or heterogeneous and can contain one or more solid or gaseous materials dissolved or suspended therein. In general, a liquid is a component of a reaction mixture that is susceptible to

- 30 evaporation under the conditions of the reaction. In particular, the liquid can be a solvent, in which a reaction is performed, for example water or glycerol/water or buffer or reaction mixture, where the reaction is performed in an aqueous

-13-

solution. The liquid can be any non-solid, non-gaseous solvent or other component of a reaction mixture that is susceptible to evaporative loss, for example, acetonitrile, which can be a solvent for a nucleic acid synthesis reaction; formamide, which can be a liquid component of a nucleic acid

5 hybridization reaction; piperidine, which is a liquid component of a nucleic acid sequencing reaction; or any other non-aqueous solvent or other liquid component. A liquid can contain dissolved or suspended components, which can be useful, for example, for initiating, terminating or changing the conditions of a reaction, thereby facilitating the performance of single tube reactions.

10 As used herein, the term "reaction mixture" refers to any mixture, including solutions and suspension, in which a chemical, physical or biological change is effected. In general, a change to a molecule is effected, although changes to cells also are contemplated. A reaction mixture can contain a solvent, which provides, in part, appropriate conditions for the change to be

15 effected, and a substrate, upon which the change is effected. A reaction mixture also can contain various reagents, including buffers, salts, and metal cofactors, and can contain reagents specific to a reaction, for example, enzymes, nucleoside triphosphates, amino acids, and the like. For convenience, reference is made herein generally to a "component" of a reaction, wherein the
20 component can be a cell or molecule present in a reaction mixture, including, for example, a biopolymer or a product thereof.

As used herein, the term "target site" refers to a specific locus on a solid support that can contain a liquid. A solid support contains one or more target sites, which can be arranged randomly or in ordered array or other pattern. In
25 particular, a target site restricts growth of a liquid to the "z" direction of an xyz coordinate. Thus, a target site can be, for example, a well or pit, a pin or bead, or a physical barrier that is positioned on a surface of the solid support, or combinations thereof such as a beads on a chip, chips in wells, or the like. A target site can be physically placed onto the support, can be etched on a surface
30 of the support, can be a "tower" that remains following etching around a locus, or can be defined by physico-chemical parameters such as relative hydrophilicity, hydrophobicity, or any other surface chemistry that allows a liquid to grow

primarily in the z direction. A solid support can have a single target site, or can contain a number of target sites, which can be the same or different, and where the solid support contains more than one target site, the target sites can be arranged in any pattern, including, for example, an array, in which the location of 5 each target site is defined.

As used herein, the term "predetermined volume" is used to mean any desired volume of a liquid. For example, where it is desirable to perform a reaction in a 5 microliter volume, 5 microliters is the predetermined volume. Similarly, where it is desired to deposit 200 nanoliters at a target site, 10 200 nanoliters is the predetermined volume.

As used herein, a small volume, typically refers to a volume on the order of nanoliters, preferably less than 1 microliter and typically, less than 0.5 microliters and less. The term nanoliter volume refers to a volume of about 0.1 to about 1000 nanoliters, preferably about 1 to 100 nanoliters.

15 As used herein, symbology refers to the code, such as a bar code, that is engraved or imprinted on a surface. The symbology is any code known or designed by the user.

As used herein, a bar codes refers a symbology that is any array of, 20 preferably, optically readable marks of any desired size and shape that are arranged in a reference context or frame of, preferably, although not necessarily, one or more columns and one or more rows. For purposes herein, the bar code refers to any symbology, not necessary "bar" but may include dots, characters or any symbol or symbols.

As used herein, the disclosed systems and methods generally are 25 useful where the reaction volume is about 500 milliliters or less; are more useful where the reaction volume is about 5 milliliters or less; are most useful where the reaction volume is in the "submilliliter" range, for example, about 500 microliters, or about 50 microliters or about 5 microliters or less; and are particularly useful where the reaction volume is a "submicroliter" reaction 30 volume, which can be measured in nanoliters, for example, about 500 nanoliters or less, or 50 nanoliters or less or 10 nanoliters or less, or can be measured in picoliters, for example, about 500 picoliters or less or about 50 picoliters or less.

For convenience of discussion, the term "submicroliter" is used herein to refer to a reaction volume less than about one microliter, although it will be readily apparent to those in the art that the systems and methods disclosed herein are applicable to subnanoliter reaction volumes as well.

5 As used herein, a "peak" or graph encompasses the visual depiction thereof and also the numerical values from which the visual depiction is generated. A mass spectrum, for example, does not have to be depicted as peaks, but can be depicted in other formats, including numerical values from which the graph of visual depiction is generated.

10 As used herein, a room refers to a space, such as a room, chamber or a hood or other enclosure that is in some manner separated. In an embodiment herein, the system is designed to operate in two rooms, such that manipulations that require sterile conditions can be performed in one room or chamber. Manipulations that do not require such conditions can be performed in a second

15 room. Samples can then be automatically transported between the first room and second room. As desired additional rooms, with conditions designed for a particular set of manipulations may be included in the system.

Automated High Throughput Integrated System

 In the automated system constructed in accordance with the disclosure

20 herein, one or more robotic systems under computer control are used to manipulate the sample of interest. The robot(s) are commanded by controlling software and move the sample between the series of reaction and sample preparation stations that comprise the system. The robot includes a robotic arm that moves, for example, along a track or on a central pivot, and is typically

25 outfitted with a "gripper" arm, allowing it to grip reaction vessels and transport them between stations. Such robotic systems are commercially available and are commonly known to those of skill in the art. For example, a robotic system and accompanying software can be obtained from Robocon Labor-und Industrieroboter Ges.m.b.H of Austria ("Robocon"). In a preferred embodiment,

30 the system is the APL automated system and it includes a Robocon "Model CRS A 255" robot, equipped with a "Digital Servo Gripper" mechanism, also available from Robocon. The robotic systems are designed such that they can be

-16-

integrated with other computer-controlled instrumentation to perform consecutive operations to effect a multi-step process.

In the preferred embodiment, one robot moves along a central track in a contamination-controlled environment, such as a positive airflow or laminar flow

5 chamber, to perform a series of manipulations or reactions on a biological sample. Once these steps are completed, the sample enters a second contamination-controlled environment, which serves as an antechamber into a non-sterile environment. The second environment can be sealed off from the first contamination-controlled environment and/or the non-sterile environment.

10 For example, in a particular embodiment, the sample is transported from the contamination-controlled laminar flow chamber into a transport chamber, or so-called "taxicab." If desired, the taxicab can provide a sterile environment as well.

Upon entry of the sample into the transport chamber, the contamination-
15 controlled environment is sealed off. The sample then moves along a pneumatically-driven or motor-driven stage in the transport chamber, and the transport chamber then opens up into the, non-sterile environment, such as an open room. In the open room, a second robot, also moving along a central track, takes control of manipulating the sample.

20 The sample to be analyzed is contained within a reaction vessel that is designed to integrate with all of the components of the system and that is amenable to the conditions of the chemical or biological reactions performed. Preferred for high throughput analysis are reaction vessels that are capable of containing multiple samples, such as multi-well microtiter plates, preferably 96-
25 well or 384-well plates or chips, such as silicon microchips. The reaction vessels also can comprise flat chips with reaction sites which are not wells, but physical locations that contain the reaction using a chemical barrier. In certain embodiments, the robot and/or gripper is adapted to hold a sample vessel. For example, pins may be added to the gripper in alignment with the wells of a
30 microtiter plate for transporting the sample.

In high-throughput applications, where multiple sample plates are to be analyzed successively in an automated fashion, the samples can be held in a

sample storage system, or rack, where they are picked up by the system robot and processed. An example of such a sample storage system, for use with multi-well microtiter plates, is the Robocon "Plate Cube" system.

In steps where sample vessels are to be sealed, such as when subjected

5 to PCR amplification, or unsealed, such as for reagent addition or removal, an automated lid application/removal and sealing system may be integrated into the system. Examples of these include a lid parking station, such as is available from Robocon, and a plate sealer, such as the "MJ Microseal", available from MJ Research. A system turntable might also be employed to assist the system

10 robot in orienting the samples for delivery into each station of the system. Such a turntable is available, for example, from Robocon. Additionally, a shaker is also included in the system in embodiments where beads, solid supports or other reagents are added to the sample for immobilizing the sample, or where other manipulations requiring mechanical shaking are involved.

15 In preferred embodiments, the sample plate or vessel is coded with a symbology, such as a bar code, which can be read by a reader, to allow sample tracking. In the preferred embodiment, separate bar code readers are contained in the contamination-controlled and non-sterile environments. Bar code systems, including one and two dimensional bar codes, readable and readable/writable

20 codes and systems therefor, are widely available, such as from Datalogic S.p.A. of Italy ("Datalogic"), and are well known to those skilled in the art.

Sample handling and reagent additions are accomplished using automated liquid handling systems. These include systems capable of automatically dispensing liquids into the sample vessel, such as through a pipette, and can be

25 adapted to any sample format, such as a multiwell microtiter plate. Such systems are commercially available, such as from Tecan AG of Switzerland ("Tecan") or Beckman Coulter, Inc. In a preferred embodiment, Tecan "Genesis 200/8" (200 cm with including an 8-tip arm) liquid handling systems, as well as a Beckman Coulter "Multimek 96" automated pipettor are used for liquid handling.

30 Other liquid dispensing systems are described in allowed U.S. application Serial No. 08/787,639 now U.S. Patent No. 6,024,925, U.S. application Serial

No. 08/786,988, and published International PCT application No. WO 98/20166, which are incorporated herein by reference.

Also present in the system may be an apparatus for preparing a test sample for analysis, including, for example, reagent addition means, or other 5 means for performing reactions or processes to prepare the sample for analysis. In certain preferred embodiments, where mass spectral analysis, specifically MALDI-TOF analysis, is to be performed using a sample array, a matrix material (i.e., an organic acid) is added to the sample using an adapted piezoelectric pipetting dispensing system. The dispensing system includes a hydrophobic tip, 10 which is capable of dispensing submolar, preferably nanomolar, samples. Such systems, as well as methods for preparing and analyzing low volume analyte array elements, have been described in allowed U.S. Patent Application No. 08/787,639, now U.S. Patent No. 6,024,925, U.S. application Serial No. 08/786,988, and published International PCT application No. WO 98/20166, 15 see, also Little *et al.*, Anal. Chem. 1997, 69, 4540-4546, the contents of which are incorporated by reference herein in their entirety.

Alternatively, a system that dispenses liquid samples from the picoliter up to the nanoliter range is commercially available, such as the "Nano-Plotter" product from GeSiM GmbH of Germany ("GeSiM"). In other embodiments, 20 reactions such as radiolabeling or adding a mass tag to the sample may be performed by the sample preparation apparatus.

A sample may also be transferred to or placed in a particular sample analysis vessel for analysis. The particular type of sample analysis vessel used is determined by the analytical method to be employed. For example, in a 25 preferred embodiment, where mass spectrometry (MALDI-TOF) is used for analysis of a sample, a typical sample vessel is a silicon microchip (< 1 square inch) that includes one or more, 100, 200, 300, 400, 500, up to 999 diagnostic sites (typically in multiples of 96, such as 96, 384 and higher densities), or even higher density, on a single chip, preferably in the pattern of a 2-D array. The 30 chip, or multiple chips, can then be placed on a sample platform, designed specifically to be inserted into the mass spectrometer.

In a preferred embodiment, the analytical system is a MALDI-TOF mass spectrometer. A preferred mass spectrometer is manufactured by Bruker-Franzen Analytik GmbH of Germany ("Bruker") and uses a UV laser. In the spectrometer, a brief pulse of laser irradiation is absorbed by the matrix, 5 leading to spontaneous volatilization and ionization of the matrix and DNA fragments. The molecular weight of the gas-phase ions are then determined by measurement of the time-of-flight of ions, which is proportional to their mass.

It should be understood that the nature of the sample to be analyzed and the analysis to be performed, as well as the feasibility of automating a reaction 10 process, determine the components integrated into the system, and the system is not to be limited to the particular embodiments described herein.

Module for performing the reaction in an unsealed environment

Systems for performing a reaction in an unsealed environment are provided in copending U.S. application Serial No. 09/266,409, filed March 10, 15 1999 and International PCT application No. PCT/US00/06288, filed March 10, 2000). These systems may be integrated into the high throughput automated systems provided herein provided herein. Briefly the systems and methods provide a means for performing reactions in an unsealed environments, such as in unsealed containers and on unsealed surfaces, by monitoring and 20 maintaining the reaction volume. The liquid generally is present on a surface of a solid support, at a target site, and the environment into which evaporation can occur is air. The systems and methods provide a means to maintain a volume of a liquid at a predetermined volume, where the volume otherwise would decrease below the predetermined volume due to evaporation. These systems 25 include a support for performing the reaction; a nanoliter dispensing pipette for dispensing an amount of a liquid onto the surface of the support; a temperature controlling device for regulating the temperature of the support; and means for controlling the amount of liquid dispensed, wherein the amount of liquid dispensed corresponds to the amount of liquid that evaporates from the support, 30 wherein the system is not sealed. Hence, inclusion of the systems for

-20-

performing the reactions in an unsealed environment are contemplated for inclusion as a module in the systems provided herein.

Analytical methods

The systems herein can be used to perform a number of different

5 reactions, dependent upon the nature of the sample and the analysis to be performed. The system is typically used to perform analysis on biological samples, typically biopolymers, including nucleic acids, proteins, peptides and carbohydrates. Methods of analysis of the biological samples include all known methods of analysis, including, but not limited to mass spectrometry (all light
10 wavelengths), radiolabeling, mass tags, chemical tags, fluorescence, and chemiluminescence, and particularly mass spectrometry.

In a preferred embodiment, the sample is a purified previously amplified portion of genomic DNA or genomic DNA sample. For analysis of DNA samples, reactions such as nucleic acid amplification (e.g., PCR, ligase chain reaction) and
15 enzymatic reactions, such as primer oligonucleotide base extension (PROBE), nested PCR or sequencing, may be performed. In addition, the apparatus can be used for hybridization (sequencing and diagnostic) reactions, and endo- and exonuclease mapping of biopolymers.

In certain embodiments, the sample may be immobilized on a solid
20 support during all or part of the automated process. For example, enzymatic reactions, including diagnostics, such as a method designated primer oligo base extension (PROBE; see, e.g., published International PCT application No. WO 98/20019 and U.S. Patent No. 6,043,031), nested PCR, sequencing, and other analytical and diagnostic procedures that are performed on solid supports (see,
25 e.g., U.S. Patent No. 5,605,798). Briefly PROBE uses a single detection primer followed by an oligonucleotide extension step to give products, which can be readily resolved by MALDI-TOF mass spectrometry. The products differ in length by a number of bases specific for a number of repeat units or for second site mutations within the repeated region. The method is exemplified using as a
30 model system the AluVpA polymorphism in intron 5 of the interferon- α receptor gene located on human chromosome 21, and the poly T tract of the splice acceptor site of intron 8 from the CFTR gene located on human chromosome 7.

-21-

The method is advantageously used for example, for determining identity, identifying mutations, familial relationship, HLA compatibility and other such markers, using PROBE-MS analysis of microsatellite DNA. In a preferred embodiment, the method includes the steps of a) obtaining a biological sample from two individuals; b) amplifying a region of DNA from each individual that contains two or more microsatellite DNA repeat sequences; c) ionizing/volatilizing the amplified DNA; d) detecting the presence of the amplified DNA and comparing the molecular weight of the amplified DNA. Different sizes are indicative of non-identity (*i.e.* wild-type versus mutation), non-heredity or non-compatibility; similar size fragments indicate the possibility identity, of familial relationship, or HLA compatibility. More than one marker may be examined simultaneously, primers with different linker moieties are used for immobilization.

As noted solid supports include, but are not limited to, flat surfaces, microtiter plates, beads, wafers, chips, and silicon support. Compositions and methods for immobilizing nucleic acids to solid supports, including methods for high density immobilization of nucleic acids are described in U.S. Patent Application Nos. 08/746,055 and 08/947,801 and published International PCT application No. WO 98/20166. Linkers for immobilizing nucleic acids to solid supports are well known. Linkers may be reversible or irreversible. A target detection site can be directly linked to a solid support via a reversible or irreversible bond between an appropriate functionality (L') on the target nucleic acid molecule (T) and an appropriate functionality (L) on the capture molecule (FIGURE 1B). A reversible linkage can be such that it is cleaved under the conditions of mass spectrometry (*i.e.*, a photocleavable bond such as a charge transfer complex or a labile bond being formed between relatively stable organic radicals).

Photocleavable linkers are linkers that are cleaved upon exposure to light (see, *e.g.*, Goldmacher *et al.* (1992) *Bioconj. Chem.* 3:104-107), thereby releasing the targeted agent upon exposure to light. Photocleavable linkers that are cleaved upon exposure to light are known (see, *e.g.*, Hazum *et al.* (1981) in *Pept., Proc. Eur. Pept. Symp., 16th*, Brunfeldt, K (Ed), pp. 105-110, which

describes the use of a nitrobenzyl group as a photocleavable protective group for cysteine; Yen *et al.* (1989) Makromol. Chem. **190**:69-82, which describes water soluble photocleavable copolymers, including hydroxypropylmethacrylamide copolymer, glycine copolymer, fluorescein copolymer and methylrhodamine 5 copolymer; Goldmacher *et al.* (1992) Bioconj. Chem. **3**:104-107, which describes a cross-linker and reagent that undergoes photolytic degradation upon exposure to near UV light (350 nm); and Senter *et al.* (1985) Photochem. Photobiol. **42**:231-237, which describes nitrobenzyloxycarbonyl chloride cross linking reagents that produce photocleavable linkages), thereby releasing the 10 targeted agent upon exposure to light. In preferred embodiments, the nucleic acid is immobilized using the photocleavable linker moiety that is cleaved during mass spectrometry. Exemplary photocleavable linkers are set forth in published International PCT application No. WO 98/20019. Bead linkers for immobilizing nucleic acids to solid supports are described in allowed U.S. application Serial 15 No. 08/746,036 now U.S. Patent No. 5,900,481, and published International PCT application No. WO 98/20166 and WO 98/20020.

Preferred applications include, but are not limited to, sequencing and diagnostics based on analysis of nucleic acids and polypeptides or diagnostics by mass spectrometry. Preferred mass spectrometric methods include ionization (I) 20 techniques including, but not limited to, matrix assisted laser desorption (MALDI), continuous or pulsed electrospray (ESI) and related methods (e.g. Ionspray or Thermospray), or massive cluster impact (MCI); the ion sources can be matched with detection formats including linear or non-linear reflectron time-of-flight (TOF), single or multiple quadrupole, single or multiple magnetic sector, 25 Fourier Transform ion cyclotron resonance (FTICR), ion trap, and combinations thereof (e.g., ion-trap/time-of-flight). For ionization, numerous matrix/wavelength combinations (MALDI) or solvent combinations (ESI) can be employed. DNA sequencing by mass spectrometry is described in U.S. Patent No. 5,547,835; U.S. Patent No. 5,691,141; and related U.S. application Serial 30 Nos. 08/467,208, 08/481,033 and 08/617,010 and in PCT Patent Application Nos. Atty. Docket No. 24736-2007PC, filed December 15, 1998, published International PCT application Nos. WO 94/16101 and WO 97/37041.

DNA sequencing using mass spectrometry is described in U.S. Patent No. 5,547,835. DNA sequencing by mass spectrometry via exonuclease degradation is described in allowed U.S. application Serial No. 08/744,590, U.S. Patent No. 5,622,824, published International PCT application No.

5 PCT/US94/02938, U.S. Patent No. 5,851,765, and U.S. Patent No. 5,872,003. Processes for direct sequencing during template amplification is described in allowed U.S. Patent Application No. 08/647,368 and published International PCT application No. WO 97/42348.

DNA diagnostics based on mass spectrometry are described in U.S. 10 Patent No. 5,605,798 and published International PCT application Nos. WO 96/29431 and WO 98/20019. Diagnostics based on mass spectrometric detection of translated target polypeptides are described in U.S. Application No. 08/922,201 and published International PCT application No. WO 99/12040. Mass spectrometric detection of polypeptides is described in U.S. Patent 15 Application No. 08/922,201 and U.S. application Serial No. 09/146,054.

It is understood that the nature of the sample to be analyzed and the analysis to be performed, as well as the feasibility of automating a reaction process, determine the methods used in the system, and the methods are not to be limited to the particular embodiments described herein. Any method and 20 process that requires small volumes and involves one or more steps in the exemplified embodiment may be adapted and used in a system as described herein.

Exemplary Embodiment

One preferred embodiment, which is a dual space system, integrates 25 nucleic acid amplification (via PCR), immobilization of the nucleic acid on a solid support, followed by enzymatic reaction (e.g., PROBE, mass array, sequencing, nested PCR), sample conditioning, addition of an organic acid matrix for MALDI-TOF analysis and MALDI-TOF analysis on a microchip. This embodiment is described with respect to the Automated Process Line (APL) system 100 30 depicted in FIG. 1. As noted above, samples are initially prepared in a contamination-controlled environment 102, such as a clean room or laminar flow room, and are moved by a sterile transport chamber 104 or taxicab into a non-

-24-

sterile environment 106.. In FIG. 1, samples are indicated by rectangular elements with criss-crossed lines.

In the FIG. 1 embodiment, sample preparation begins in a Liquid Handling System 108, such as the Tecan "Genesis 200/8 Robotic Sample Processor"

5 product. One or more samples 110 of purified genomic DNA are delivered by a robot 112 to 96-well or 384-well microtiter plates 114 in the Liquid Handling System 108, preferably using a 200 cm instrument width and an 8-tip arm. These sample processing steps occur in the contamination-controlled environment 102. Multiple samples may be included in the APL system for high-
10 throughput processing. These samples may, at times during processing, be held in a sample storage apparatus, such as the "Plate Cube" rack 116 available from Robocon. To the sample plates 114 are added a PCR reaction mix 118, including PCR primers, where one of the primers is labeled at the 5' end with functionality, such as biotin, that can be used to immobilize the amplicon to a
15 solid support is added to the sample mixture. Where multiple samples are to be processed, a wash solution is contained in a reservoir 120 and is used to clean the pipette tips to prevent cross-contamination between samples or reagents. Alternatively, the APL system can process multiple samples using disposable pipette tips.

20 The sample plates are manipulated by a robotic system, for example the Robocon robot 112, such as the CRS A 255 Robot, which moves along a central track 122. The robot 112 operates under control of a clean room control system computer 124 that includes a central processing unit (CPU) 126, a operator interface 128, and an APL interface 130. The CPU can comprise any
25 commercially available desktop computer, such as an IBM-compatible personal computer (PC) or the like. The operator interface 128 includes a visual display and keyboard or other device through which an operator provides commands. The APL interface 130 is an interface between the computer and the process line, through which the computer 124 controls the robot. The APL interface
30 may include, for example, a robot control program installed in the computer 124 and available from Robocon for control of its robot products. An optional second

computer 131 can assist the first computer 124 in performing clean room processing.

The robotic arm is equipped with a gripper 132, such as the "Digital Servo Gripper" arm, also available from Robocon, to pick up and drop off the 5 sample plates 114 as needed, for processing. In a particular embodiment, a microtiter plate is aligned with the gripper so the plate receives pins 134 of the gripper, which more securely couple the plate with the gripper for more secure transport.

FIG. 1 shows a sample plate 140, including the sample and PCR mix, that 10 is moved to a turntable 142 and oriented such that the robot picks it up and moves it to a bar code reader 144, for example, as is available from Datalogic, where the bar code is read and recorded for sample tracking. Sample tracking and reorientation may be performed multiple times during sample processing to assist the robot in sample handling.

15 The sample plate 140 is reoriented by the robotic arm, using the turntable, and is then placed in a lid parking station 146, such as is available as a robotic module in the Robocon robotic system. At the lid parking station, a lid may be parked or retrieved. In the preferred embodiment, the lid is a solid structure, such as a metal lid, with a flexible seal such that placing the lid on the 20 plate seals the contents of the plate. The sealing eliminates evaporation during subsequent processing, such as PCR amplification. Such a sealing apparatus, known as "MJ Microseal", is available from MJ Research, Inc. Alternatively, after the sample plate is reoriented, it can be penetrably sealed. For example, the sample plate can be covered with a foil wrap that can later be penetrated by 25 test probes or the like. A similar penetrable seal can be provided by a parafilm that is attached to the plate by heat, or other plastic or wax based sealers.

The sealed sample plate is then picked up by the robotic gripper arm and transported from the laminar flow environment 102 into the taxicab transport station 104, which provides a sterile environment. First, an entry door opens in 30 the taxicab to permit the robot to place the sample plate into the taxicab. Once in the taxicab 104, the entry door closes behind the sample to prevent contamination. Within the taxicab transport station 104, the sample plate is

-26-

placed onto and is transported along a pneumatically driven stage, and a second door opens to permit the sample to exit the taxicab into a non-sterile environment. Once outside the sterile taxicab environment, control of sample manipulation is transferred to a second robot 150, also equipped with a gripper

5 152 and moving along a center track 153. The sample plate is transported by the robot 150 and is read by a second bar code reader 154 for sample tracking. The second bar code reader 154, as well as a second turntable 156, lid park station 158 and sample storage rack 160 are included outside the contamination-controlled area 102 for more efficient sample handling.

10 The robot 150 operates under control of a PCR Room computer 161 that has a construction similar to the Clean Room computer 124. Thus, the PCR Room computer 161 can comprise any commercially available desktop computer that can interface with the APL system process line and stations.

After the sample identification code has been read by the bar code reader

15 152, the sample plate is moved by the system robot 150 to a PCR station 162, where amplification is carried out. The amplification reaction can be PCR, ligase chain reaction, etc. In a preferred embodiment, the "MJR Tetrad" thermocycler, available from MJ Research, Inc., is used for PCR amplification. Other PCR thermocycler systems are commonly known to those of skill in the art and may

20 optionally be integrated into the system. Methods for DNA amplification are well known to those of skill in the art. Multiplex PCR can also be carried out using the system.

After PCR amplification, the plates are removed from the PCR reaction station 162 by the robot 150. The plates are then moved to the lid park station

25 158, where the lids are removed and unsealed. As noted above, however, a penetrable seal such as a foil wrap or parafilm is an alternative to a lid seal, and if removable lids are not used to seal the plates, then the lid park station is unnecessary and the next substance that must be added to the wells of the plate will be inserted upon piercing of the foil wrap.

30 Alternatively, using a second liquid handling system 164, preferably a Tecan "Genesis 200/8" system, streptavidin-coated paramagnetic beads can be loaded from a reservoir 166 and mixed with the PCR-amplified DNA in the

sample plate, resulting in immobilization of the amplicon via the functionalized (e.g. biotinylated) primer. Beads are used, for example, where the samples are contained in multiwell microtiter plates. The beads and PCR products are reacted by shaking, using a shaking apparatus 168, such as is available from

5 Robocon, and which is integrated into the APL system.

The sample plates are then moved to a liquid handling and mixing station 170, into which a magnetic lift station 172 has been incorporated, for post-PCR processing. In a preferred embodiment, the liquid handling station is a "Multimek 96" well pipetting station, available from Beckman. The magnetic lift 10 applies magnets to the sample plate by moving the magnets up against the bottom of the sample plate, for example, by using a pneumatic lift, thereby immobilizing the DNA and beads, and the supernatant is removed. The magnets are then released and liquid is added to the wells to resuspend the sample. Alternatively, the sample plate could be moved, for example, by the robot to 15 bring it into contact with the magnet. The magnet can be a solid surface that interacts with the entire bottom of the sample plate, or can be designed to more specifically interact with the individual samples. For example, where the sample plate is a 96-well microtiter plate, the magnet can be configured as 8 or 12 individual strips so that each strip comes into contact with the bottom of a 20 single row of wells.

Conventionally, the magnets of the magnet lift station 172 are elongated, strip magnets arranged in rows between sample wells. Alternatively, the magnets can be configured as individual point magnets, for example, as disk-shaped magnets arranged into an 8 x 12 grid of magnets that correspond to the 25 positions of the sample wells in a 96-well microtiter plate. This configuration provides an advantage over the magnetic strip configuration, particularly where small volumes are to be added to the sample. For example, as illustrated in FIG. 2, where magnetic strips 202 are used with a multiwell microtiter plate 204, the magnet strips are offset from the center of the sample wells 206, and 30 magnetic beads 208 concentrate along the sides of the wells.

It is desirable that all beads be concentrated in a location such that added liquid makes maximum contact with the samples. If, for example, a volume of

sample is removed from the wells and a smaller volume is to be subsequently added, the smaller volume might not be sufficient to wash all the beads from the side of the wells, and the sample concentration could be affected. FIG. 3 is a plan view of the alternative, preferred embodiment, and shows a portion of the 5 construction that centers a disk-shaped point magnet 302 beneath the center of each sample well in a multiwell microtiter plate. For simplicity of illustration, only a 4X5 grid is shown. It should be apparent that by using individual point magnets at the bottom of the wells, the beads collect at the bottom of the wells and are more easily resuspended, particularly where a smaller volume of liquid is 10 to be added. Multiple rounds of liquid handling are employed to allow for supernatant removal, denaturation of double stranded DNA, wash steps and the addition of enzymatic reaction reagents (PROBE).

Returning to FIG. 1, a sample plate 176 is next moved by the robotic system to the lid park station 158, and sealed with a lid. This operation is 15 optional and is used, for example, when the sample is subjected to high temperatures in order to prevent evaporation. The sample plate can otherwise remain open to the environment.

The robot 150 moves the sample plate again to the PCR station 162 and places it into a thermocycler of the PCR station. The thermocycler carries out an 20 enzymatic reaction. The enzymatic reaction can be, for example, PROBE, nested PCR, primer extension, or sequencing reactions (e.g. Sanger). Details for such enzymatic reactions are commonly known to those skilled in the art.

After the reaction is complete, the sample plate is removed from the thermocycler of the PCR station 162 and then is returned to the lid park station 25 158 by the robot 150, and the lids are removed and the plate unsealed.

The sample plates are again moved to the liquid handling and mixing station 170 containing the magnetic lift station 172, which applies the magnets, immobilizing the beads and DNA. The liquid handling and mixing station then removes the supernatant. The magnets are then released and liquid is added to 30 the wells. Multiple rounds of liquid handling are employed to allow for washing steps or treatment with ammonium citrate, TRIS, or any other reagent that removes salt ions and replaces them with ammonium ions, thereby conditioning

the samples prior to mass spectrometry. Once conditioned, the primer extension product is denatured from the immobilized DNA with ammonium hydroxide and released into the supernatant. The ammonium hydroxide reaction is performed for five minutes at approximately 60° F. The supernatant is removed to a clean

5 sample plate and placed on a shaker 168.

The sample plate is next transported to a sample preparation station 178 to prepare it for analysis. In a preferred embodiment, where MALDI-TOF mass spectral analysis is performed, nanoliter or smaller volumes of sample are dispensed onto pre-made silicon chips to form a microarray and reacted with

10 matrix. In general, however, the sample may involve any preparation for use with any analytical method. Nanoliter or smaller volumes are dispensed using a nanoliter or lower dispensing apparatus, such as a piezoelectric pipette, including the "Nano-Plotter" station, available from GeSiM. Finally, the sample plate is transported to the analytical system, e.g., a mass spectrometer or other

15 spectrometric techniques, such as UV/VIS, IR, fluorescence, chemiluminescence or NMR spectrometry, where sample analysis is performed.

Several alternatives are possible for preparing a sample for analysis and loading the sample into the analytical system. For example, three separate components, including a dispensing apparatus, a sample platform containing test

20 samples, and an analytical instrument, can be integrated into the APL system.

In a preferred embodiment, a nanoliter dispensing apparatus ("Nano-Plotter") 180 of the sample preparation station 178 is used to prepare one or more samples for mass spectral (MS) analysis, preferably using MALDI-TOF MS. In preparing a sample for MALDI-TOF analysis, the sample is co-crystallized with

25 a matrix material. The sample is then loaded into a mass spectrometer 182 on a MS sample platform. Alternatively, the MS platform may be integrated into the mass spectrometer, rather than a separately-controlled component. The sample platform can be adapted to hold one or more sample analysis vessels, such as microchips.

-30-

In another embodiment, the APL system can carry out enzymology directly on the beads and can directly add matrix to the beads to analyze using mass spectrometry, where the DNA is ionized directly off the beads. This eliminates the need for a nanoliter dispensing station 178 such as the GeSiM

5 "Nano-Plotter", rather, matrix is added with the liquid handling system 170.

In a preferred embodiment, one or more microchips containing test samples are prepared by dispensing nanoliter volumes of a sample and an organic acid matrix onto a chip using a nanoliter dispensing apparatus 180, or a nanoliter dispensing apparatus, and loading the chips into a mass spectrometer

10 182. Alternative embodiments are possible where (1) one or more test samples, e.g., on sample chips, are prepared on a sample platform on the nanoliter dispensing apparatus, such as the Nano-Plotter, and the sample platform is then transferred, e.g., by a robot, into the mass spectrometer; or (2) where one or more sample chips are prepared on the nanoliter dispensing apparatus,

15 transferred to a mass spectrometer sample platform station 184 and then inserted into the mass spectrometer.

In another embodiment, the APL system can carry out enzymology directly on a microchip by performing the steps of:

1. Aliquot genomic DNA and transfer to second chamber via taxi;
- 20 2. PCR amplify the genomic DNA using previously described steps;
3. Using a liquid handling apparatus (Tecan or GeSim) or pintoool add DNA to microchip. The chips are held in a holder that can be manipulated by the robot;
4. Add PCR reaction mix to chip;
- 25 5. Incubate on thermocycler;
6. Wash chip with liquid handling apparatus;
7. Add matrix to chip;
8. Load chip in MALDI; and
9. Ionization/Desorption directly from the chip via MALDI.

Mass Spectrometer Interface

The nanoliter dispensing apparatus and mass spectrometer are integrated into the system 100 and communicate with each other, either directly or via a control computer. For example, in one embodiment, commands are

- 5 automatically executed from a computer controller to initiate opening and closing of a mass spectrometer entry door (e.g., by using pneumatics or a motor-driven mechanism) and to initiate loading of a MS sample platform into the spectrometer (e.g., by using a robotic arm), where the platform is either loaded with sample chips directly on a nanoliter dispensing apparatus, such as the
- 10 Nano-Plotter 180, or the sample chips are prepared on a nano-plotter 180 and then are transferred onto a sample platform 184. FIG. 4 shows one implementation of the robotic interface between the nanoliter dispensing apparatus and the mass spectrometer illustrated in FIG. 1.

In the FIG. 4 embodiment, the samples are automatically transported from 15 the sample preparation station 178 to the mass spectrometer 182 by a robotic arm system 410 (not shown in FIG. 1). As described above, the samples are prepared for the mass spectrometer 182 in the nanoliter dispensing apparatus 180 and/or the sample platform station 184. When preparation is complete, an 20 arm 412 rotates about a pivot base 414 to pick up the samples from the sample preparation station and then positions them at a sample entry station 416 of the mass spectrometer.

Data Analysis

Conventionally, the output of mass spectrometer testing is analyzed by an individual datum-by-datum, so that an individual examines the output of a 25 sample test and makes a conclusion about the test, sample-by-sample. In the Automated Process Line (APL) described above, the volume of test results is sufficiently large that any individual analyzing the mass spectrometer output would quickly be unable to keep up with the APL output pace. The APL system of the preferred embodiment performs computer-automated analysis of mass 30 spectrometer output data to determine genotype or make another analysis as quickly as the system produces test results. The data analysis can continue as long as the system is in operation, including on a round-the-clock, 24-hour basis.

The APL system performs the test output analysis by automatically processing the mass spectrum output data of a sample, comparing the output data against expected spectrum output values for different genotypes, producing a conclusion about the sample genotype based on a conclusion about most likely genotype for 5 the sample, and continuing with the output data of the next sample.

In the preferred embodiment illustrated in FIG. 1, the data analysis is performed by a dedicated data analysis computer 188 that receives output data from the mass spectrometer 182 and any other pertinent APL stations or components. The data analysis computer can comprise any commercially 10 available desktop computer, and can have the same configuration and components as the Clean Room control computer 124 described above. Thus, the data analysis computer 188 includes a CPU having an operating environment in which programs are executed, and also includes an operator interface with a keyboard and a display.

15 The process line 100 operates continuously until a stop command is received, for a high sample throughout. Therefore, the process line provides for emergency situations where an immediate halt is required by providing halt switches 198 placed around the line. The system also can be halted by a software halt command that is input by an operator at any of the control 20 computers 124, 131, 161, 188. The sample preparation, testing, and data analysis otherwise continues unimpeded.

25 A visual display of the data analysis is depicted in FIG. 5, which shows from top to bottom: a graph of two exemplary test spectra against which output data will be compared; a graph of output data picked peaks for analysis; and a graph of smoothed spectrum data. Those skilled in the art will appreciate that the spectra shown in FIG. 5 correspond to multiple graphs of mass spectrometer output, wherein the horizontal axis (x-axis) units are in mass per unit charge, also referred to as units of Daltons, and the vertical axis (y-axis) is in relative intensity of spectrometer discharge.

30 The exemplary spectra shown in FIG. 5 relate to male-female genotypes, but those skilled in the art will appreciate that any other paired-outcome typing decisions may be the subject of the sample analysis.

In FIG. 5, the first test spectra is labeled "Test--Female" and corresponds to output spectra that might be expected from a female test subject. The second test spectra is labeled "Test--Male" and corresponds to output spectra that might be expected from a male test subject. Thus, the object of the APL processing will be to determine whether a given sample genotype belongs to a female subject or a male subject. The "Picked Peaks" of FIG. 5 spectra is a display of the mass spectrometer output for a particular sample over a predetermined range, to show particular output peaks. The output peaks shown in the Picked Peaks graph are selected by the APL system based on input 5 parameters supplied by the APL operator, as described further below. The bottom spectra of FIG. 5 is a display of the spectra output after correction processing initiated by the APL system. It should be understood that the Test--Female and Test--Male graphs of the FIG. 5 display will not change as the APL 10 system processes the mass spectrometer output data, while the Picked Peaks and Smoothed Spectrum graphs are different for each sample data, and therefore 15 will generally change with each sample being processed. It also should be understood that the Picked Peaks and Smoothed Spectrum displays can be stopped on any one of the output graphs, if the operator wants to view one particular set of graphs. FIG. 6 is a flow diagram of the operating steps 20 performed by the APL system in carrying out the mass spectrometer data analysis, and will be best understood with reference to the FIG. 5 graphs.

The first data analysis step, represented in FIG. 6 by the flow diagram box numbered 602, is to receive test run input parameters. These are 25 parameters that the APL system will receive from an operator and will apply in processing a run of mass spectrometer output data. That is, the APL system will use the test run input parameters to evaluate test samples until the test run parameters are changed by the APL operator. As noted above, a test run might involve producing mass spectrometer output and analyzing it on a 24-hours-per-day basis. In the preferred embodiment, the operator provides the test run 30 parameters through a graphical user interface using a display mouse and keyboard of the APL system. The test run input parameters received from the operator will include the x-axis range in Daltons for the spectrometer output data

-34-

and x-axis locations of expected peaks that are picked for data identification and genotype evaluation. The input parameters will also include an expected baseline value, defining a noise floor above which data should comprise a peak.

In the next processing step, represented by the FIG. 6 flow diagram box 5 numbered 604, test data is received for a particular test sample submitted to the mass spectrometer of the APL system. A particular test sample may be one well in a 96-well-by-96-well tray, for example. Other tray sizes may be accommodated by the APL.

Those skilled in the art will understand that a mass spectrometer 10 bombards a crystalline-based sample with energy until the sample vaporizes and output products are produced. The output products include intact sample particles that are ionized and projected outwardly to different distances from the sample center. The mass spectrometer detects the distribution of output products having a particular mass per unit charge and assigns a relative intensity 15 to those output products. The mass/charge units are given in Daltons or kiloDaltons (kD). Thus, the mass spectrometer output for a given sample is a sequence of paired numbers, or x-y values, that specify the detected mass/charge over a range of Daltons (x-axis) and the corresponding relative intensity (y-axis) distribution over that range.

20 For each set of sample data that is processed, the APL system removes the residual baseline. This processing is represented by the FIG. 6 flow diagram box numbered 606, and allows for a rolling baseline that might otherwise skew the output data. More particularly, with current processing systems, it is possible to misinterpret peaks or spikes, such as where true data peaks are 25 located in valleys. Conventional programs identify peaks by detecting data intensity values (see FIG. 5) that are greater than a baseline value. The data, however, can contain localized areas in which a peak lies within a valley of a plateau area having an elevated baseline. Peaks that are in such valleys may be missed by conventional programs that do not detect a sufficient difference 30 between the peak height relative to the plateau level. It has been found that such conventional programs may correctly identify peaks up to 80% of the time, but cannot generally provide greater accuracy due to missed peaks.

-35-

To remove the residual baseline and increase accuracy, the APL data analysis receives the input parameters that contain the operator's specification of where the peaks in the sample experimental results should be located in the mass spectrometer output. The APL system then examines the output data

5 where there should be no peaks to find the true baseline value. The processing represented by the FIG. 6 flow diagram box numbered 606 therefore includes modeling the baseline of the mass spectrometer output with a quadratic equation, based on the test run inputs from the operator. It has been found that a quadratic equation is superior to using a cubic equation, and also closer than a

10 15 lower-order fit, even though very small coefficients are expected for the baseline curve fit.

For example, the range of interest might be mass spectrometer output over the range of 4000 to 9000 Daltons. The maximum range and minimum range would be received as test run inputs. In addition, the expected peaks for the sample experimental data over that range of interest would be received as test run inputs. The data concerning expected peaks should include the peaks that will be produced given the data types for which there is testing, and also peaks expected in the output as a result of primer substances in the sample. Thus, the range of interest should include output artifacts from primer sources.

20 25 These primer output artifacts can serve as landmarks to identify any output shifting. In addition to the locations of the expected peaks, the APL system also receives the peak width as an input test run parameter. The APL system assumes that peaks will be distributed as a gaussian curve, and the peak width input parameter indicates the approximate width for each of those peaks. In the preferred embodiment, there is one input for all peaks. For example, all peaks may be specified as having a width of 10 Daltons (ten x-axis units).

Next, with the test run parameters that specify the range of interest and the location of peaks, the APL system will identify peak-free regions in the mass spectrometer output of each sample that correspond to the range of interest,

30 with the data at the peaks removed. For example, suppose there are two peaks of interest expected in the output that will identify a sample as being one genotype or another. Suppose also that there is an additional peak expected in

the output, for primer output artifacts. Therefore, a total of three peaks will be expected in the mass spectrometer output over the range of interest. Then the peak-free regions would be those regions in the output data along the x-axis over the range of interest, with the data at the three identified peaks deleted. As

5 noted above, the peaks are assumed to be gaussian, with a width value specified in the input parameters. Therefore, the data for deletion comprises the peaks identified in the test run input parameters and also an area two peak widths wide on either side of each identified peak (peak midline, +/- two peak widths).

10 It is the mass spectrometer output data with the peaks deleted that gives the peak-free region, to which the quadratic equation is fitted. Typically, the variable quadratic coefficients would be small, but it is possible to get contamination from the lower-mass sample particles, which can skew the output. If such contamination is present in the output, then the sample output
15 may be skewed so that the peak free regions will be best modeled by a quadratic equation. It has been found that contamination products are best modeled with a quadratic equation, rather than a linear, cubic, or other type of equation.

The technique for determining the coefficients of the quadratic equation for the best fit to a peak-free baseline is preferably a least squares fit technique,
20 which will be well-known to those skilled in the art. In particular, error minimization using gradient information has been found suitable for the least squares fit. Thus, the curve-fit quadratic baseline equation can be used to produce an expected baseline over the mass spectrometer output range of interest. Therefore, as part of the baseline correction processing represented by
25 the FIG. 6 flow diagram box numbered 606, at each data point interval along the range of interest (e.g., from 4000 to 9000 Daltons), the curve-fit baseline equation is used to calculate a corrected baseline value, which is subtracted from the sample data. The baseline correction occurs over the entire data range, including at the peaks. This produces a new set of baseline-corrected sample
30 data values, i.e., a baseline-corrected output spectrum.

In the next processing step, represented by the FIG. 6 flow diagram box numbered 608, a curve is fit to each baseline-corrected peak value in the mass

spectrometer output data. In the preferred embodiment, a standard curve fitting algorithm is used, such as the Marquardt-Levenberg algorithm. This fits a gaussian curve to each possible baseline-corrected output peak position. Those skilled in the art will understand that the output of such curve fitting will provide

5 coefficients of a gaussian distribution centered at each peak that will match the height of the baseline-corrected output data at that peak, and will also provide the covariance of the curve-fit height. Thus, the box 308 curve fitting will provide, for each peak, equation coefficients that give a peak height and a covariance for the equation at that peak.

10 In a preferred embodiment, the "Picked Peaks" graph in FIG. 5 represents all peaks in the mass spectrometer output that have a height that exceeds the baseline corrected value generated by the box 606 processing, using peaks that are modeled from the box 608 processing. Alternatively, the Picked Peaks graph may represent the peaks in the actual mass spectrometer output that exceed an

15 input threshold value. This latter type of Picked Peaks graph display is the type that is typically provided by mass spectrometer manufacturers, such as Bruker-Franzen Analytik GmbH ("Bruker") of Germany. In the preferred embodiment, the "Smoothed Spectrum" graph of FIG. 5 represents the output from the mass spectrometer with default data processing, which may include

20 curve smoothing or other data processing provided by the mass spectrometer manufacturer. This type of Smoothed Spectrum graph is provided, for example, as standard output from the Bruker mass spectrometer. Alternatively, the Smoothed Spectrum graph may represent the mass spectrometer output with the baseline threshold parameter subtracted, or the actual mass spectrometer output

25 with the quadratic-fit baseline curve subtracted.

In the next processing step, represented by the FIG. 6 flow diagram box numbered 610, the APL system determines the probability that the output data at each identified peak location is a valid peak. In the preferred embodiment, the peak validation decision is made by comparing probability density functions

30 (PDF) for the peak-free region and for the fitted peak by constructing gaussian (or normal) probability curves and comparing them to determine if the data overlaps. If the two curves (the fitted peak and the peak-free region) are

-38-

substantially free of any overlap, then the APL assumes that a true peak has been identified. Otherwise, the fitted "peak" is considered a spurious datum in the noise of the mass spectrometer output.

More particularly, the PDF of the peak-free region is assumed to be a gaussian distribution. The mean height and the standard deviation are determined by the mass spectrometer output for the sample in question. The PDF at each identified peak location is assumed to be a gaussian distribution with the mean height and the standard deviation given by the curve fitting algorithm described in box 308. The second gaussian curve will be determined once for each peak. The degree to which the two curves resemble each other is compared statistically using hypothesis testing that will be well-known to those skilled in the art. The output of the hypothesis test will be a probability value (from zero to one) that characterizes the peak under consideration. Thus, each peak is assumed to be an independent statistical event.

For example, the comparison uses the baseline curve, which is a quadratic model (peak-free region) having a particular mean height and corresponding standard deviation. The comparison also uses the gaussian model of each peak, having a mean height and standard deviation. If the mean values of the two respective curves are different by more than two standard deviations, then it is assumed there is no overlap for purposes of peak validation. That is, the test peak is a valid peak. If the two curves are not different in mean by more than two standard deviations, then the identified peak is not a valid peak, but is part of the output noise.

After the APL system evaluates the probability for all of the peaks, it will know the number of peaks that have been identified as valid. The system then determines probabilities for the genotypes under consideration. The APL system makes a data typing decision based on the presence or absence of sufficient true or validated peaks to indicate one genotype or the other. This processing is indicated in FIG. 6 by the flow diagram box numbered 612, and is carried out in a probabilistic manner.

For example, suppose a sample is to be typed as either female or male, and a female is indicated by the presence of an output peak at a position "A"

-39-

and the absence of an output peak at a position "B", while a male is indicated by a peak at position "A" and also at position "B". Then the probability of a sample being female is the product of the probability of a true peak occurring at A and the probability of a peak not occurring at B. Stated in equation form:

5 $P(\text{female}) = P(A) * (1 - P(B)).$

The probability of a sample being male is then the product of the probability of a true peak occurring at position A and the probability of a true peak occurring at position B, given by the equation:

$$P(\text{male}) = P(A) * P(B).$$

10 This analysis is performed automatically by the APL system for each of the samples processed by the mass spectrometer. Based on these probabilities, the APL system decides whether the mass spectrometer output identifies a male or a female. If the probabilities indicate an ambiguous outcome, then the mass spectrometer output is considered inconclusive. In the preferred embodiment, a 15 probability is considered conclusive if it is at least ten times the probability of the alternative outcome. Thus, if $P(\text{female})$ is greater than ten times $P(\text{male})$, then the typing decision is for a female. If $P(\text{male}) > 10 * P(\text{female})$, then the typing decision is for a male.

20 After the analysis has been performed for a sample subject, the APL system checks for additional mass spectrometer output for analysis. As noted above, the APL system can support mass spectrometer output at the rate of hundreds of output sets per hour. As indicated by the decision box 614 in FIG. 6, if more data is present, an affirmative outcome at box 614, then APL control resumes with receiving the next set of output data at the flow diagram box 25 numbered 304. If there is no more mass spectrometer output data for analysis or if a system operator indicates a halt command, a negative outcome at box 614, then the sample run ends and other operation of the APL continues. For example, operation may return to box 602, where more test run input parameters are received and output analysis is resumed. Other processing may 30 occur, as desired.

Databases

In cases of high-throughput, the system stores results of all samples in all runs in a database. The sample run history may be selected for viewing through a user interface, such as, but are not limited to, that illustrated in FIG. 7.

- 5 The user interface permits review of the database created by one or more sample runs. An example of the user interface to such a database is shown in the screen display of FIG. 8. The database provides a means of obtaining test output, reaction details, sample details, and assay details for each sample under test. For example, shown as output collected in the database are the sample
- 10 plate number, location of the sample well, sample and plate IDs, name, result of genotype matching, and actual spectrum for each sample.

A database analysis system is also integrated into the APL system (see FIG. 7) and permits a user to (1) create a new run; (2) copy an existing run; (3) edit or view an existing run; (4) change status or add comment; (5) view the history of a run; and (6) create or edit an assay or test. In the preferred embodiment, the database is supported by a database management system from Oracle Corporation.

The systems may also draw from data available in databases or collected in databases. Of interest and exemplary, though not limiting, thereof, is the

- 20 healthy patient database described in copending U.S. provisional application Serial No. 60/159,176, filed October 13, 1999.

The processes, systems, and products provided herein have been described above in terms of a presently preferred embodiment. There are, however, many configurations for automated high throughput systems that

- 25 include processing stations not specifically described herein but that are apparent from the disclosure herein. The disclosure herein is not limited to the particular embodiments described herein, but rather, is understood to have wide applicability with respect to automated process lines generally, particularly in the areas of diagnostics and high throughput screening protocols.
- 30 Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

CLAIMS:

1. An automated system for high throughput processing of biological samples, the system comprising:
 - a plurality of processing stations, each of which performs a procedure on
 - 5 a biological sample contained in a reaction vessel, wherein one of the processing stations comprises a mass spectrometer;
 - a robotic system that transports the reaction vessel from processing station to processing station;
 - a data analysis system that receives test results of the processing
 - 10 stations and automatically processes the test results to make a determination regarding the biological sample in the reaction vessel; and
 - a control system that determines when the test at each processing station is complete and, in response, moves the reaction vessel to
 - 15 the next test station, and continuously processes reaction vessels one after another until the control system receives a stop instruction.
2. A system of claim 1, wherein the reaction vessel comprises a multiple-well substrate or a solid support or both.
- 20 3. A system of claim 1 or claim 2, further including a mass spectrometer interface that automatically transfers samples into the mass spectrometer for processing.
4. A system of any of claims 1-3, wherein the data analysis system processes the test results from the mass spectrometer and makes a data typing
- 25 decision regarding the biological sample.
5. A system of any of claims 1-4, wherein the data analysis system processes the test results by receiving test data from the mass spectrometer such that the test data for a biological sample contains one or more peaks, whereupon the data analysis system removes a residual baseline from the test
- 30 data for a biological sample, curve fits each peak of the biological sample test data to predetermined input parameters, determines a probability that each peak of the biological sample test data is a valid peak, and makes a data typing

decision regarding the biological sample in accordance with the determined valid peaks.

6. A system of any of claims 1-5, wherein the data analysis system displays exemplary test spectra for data types determined by the data analysis system, along with a graph of test data picked peaks and a graph of smoothed test spectra data for a biological sample.

5 7. A system of any of claims 1-6, wherein the data analysis system receives test run input parameters that determine processing until a different set of input parameters is received.

10 8. A system of any of claims 1-7, wherein the data analysis system removes the residual baseline from the test data by modeling the baseline of the mass spectrometer data with a quadratic equation specified by the input parameters.

15 9. A system of claim 8, wherein the input parameters specify a range of data over which the baseline is modeled.

10. A system of claim 9, wherein the baseline is modeled over a peak free region specified by the input parameters.

11. A system of claim 7 or claim 8, wherein the picked peaks graph represents all peaks in the mass spectrometer output that have a height that 20 exceeds the residual baseline corrected data.

12. A system of claim 11, wherein the data analysis system validates a peak after comparing a probability density function for the peak free region with a probability density function for a fitted peak if the comparison shows that the respective probability density functions overlap by a predetermined amount.

25 13. A system of any of claims 1-12, wherein the process line includes a contamination-controlled environment and a non-sterile environment, each environment containing one or more processing stations.

14. An automated system for high throughput processing of biological samples, the system comprising:

30 a process line comprising a plurality of processing stations, each of which performs a procedure on a biological sample contained in or on a reaction vessel;

-43-

a robotic system that transports the reaction vessel from processing station to processing station;

a data analysis system that receives test results of the process line and automatically processes the test results to make a determination

5 regarding the biological sample in the reaction vessel;

a control system that determines when the test at each processing station is complete and, in response, moves the reaction vessel to the next test station, and continuously processes reaction vessels one after another until the control system receives a stop

10 instruction; and

a contamination-controlled environment and a non-sterile environment, each environment containing one or more processing stations.

15. The system of any of claim 13 or claim 14, further comprising a taxicab that automatically transports samples between the two environments.

16. A method for high throughput processing of biological samples, the method comprising:

20 transporting a reaction vessel along a process line of the system of any of claims 1-15 having a plurality of processing stations, each of which performs a procedure on one or more biological samples contained in the reaction vessel;

determining when the test procedure at each processing station is complete and, in response, moving the reaction vessel to the next processing station;

25 receiving test results of the process line and automatically processing the test results to make a data analysis determination regarding the biological samples in the reaction vessel; and

processing reaction vessels continuously one after another until receiving a stop instruction.

30 17. The method of claim 16, wherein the step of transporting includes automatically transferring samples into a mass spectrometer for processing using a robotic mass spectrometer interface.

-44-

18. A method of claim 16, wherein the step of receiving test results comprises:

receiving test data from the mass spectrometer such that the test data for a biological sample contains one or more peaks;

5 removing a residual baseline from the test data for a biological sample; curve fitting each peak of the biological sample test data to predetermined input parameters;

determining a probability that each peak of the biological sample test data is a valid peak; and

10 making a data typing decision regarding the biological sample in accordance with the determined valid peaks.

19. A method of claim 16, further including the step of displaying exemplary test spectra for data types to be determined by the data analysis system, along with a graph of test data picked peaks and a graph of smoothed 15 test spectra data for a biological sample.

20. A method of claim 16, wherein the data analysis system receives test run input parameters that determine processing until a different set of input parameters are received.

21. A method of claim 20, wherein the step of displaying comprises 20 displaying exemplary test spectra for data types to be determined by the data analysis system, along with a graph of test data picked peaks and a graph of smoothed test spectra data for a biological sample, and the input parameters specify display parameters.

22. A method of claim 16, wherein the step of removing residual 25 baseline from the test data comprises modeling the baseline of the mass spectrometer data with a quadratic equation specified by the input parameters.

23. A method of claim 22, wherein the input parameters specify a range of data over which the baseline will be modeled.

24. A method of claim 23, wherein the baseline is modeled over a 30 peak free region specified by the input parameters.

25. A method of claim 21, wherein the picked peaks graph represents all peaks in the mass spectrometer output that have a height that exceeds the residual baseline corrected data.

26. A method of claim 25, wherein the data analysis system validates 5 a peak after comparing a probability density function for the peak free region with a probability density function for a fitted peak if the comparison shows that the respective probability density functions overlap by a predetermined amount.

27. A method of claim 16, wherein the process line includes a contamination-controlled environment and a non-sterile environment, and the 10 step of transporting includes automatically transporting samples between the two environments in a sterile taxicab.

28. A data analysis system comprising:

15 a computer having an operating environment that executes a data analysis program for processing test results from a process line of any of claims 1-15 having a plurality of processing stations, each of which performs a procedure on a biological sample contained in or on a reaction vessel; and

20 a computer interface that receives the test results from the process line and provides the test results to the data analysis program; wherein the data analysis program automatically processes the test results to make a determination regarding the biological sample in the reaction vessel, and continuously performs such processing for biological samples until a stop instruction is received.

25 29. A data analysis system of claim 28, wherein the data analysis system processes the test results by receiving test data from the mass spectrometer such that the test data for a biological sample contains one or more peaks, whereupon the data analysis system removes a residual baseline from the test data for a biological sample, curve fits each peak of the biological sample test data to predetermined input parameters, determines a probability 30 that each peak of the biological sample test data is a valid peak, and makes a data typing decision regarding the biological sample in accordance with the determined valid peaks.

30. A data analysis system of claim 28 or claim 29, wherein the data analysis system displays exemplary test spectra for data types to be determined by the data analysis system, along with a graph of test data picked peaks and a graph of smoothed test spectra data for a biological sample.

5 31. A data analysis system of any of claim 28 or claim 29, wherein the data analysis system receives test run input parameters that determine processing until a different set of input parameters are received.

32. A data analysis system of claim 31, wherein the data analysis system displays exemplary test spectra for data types to be determined by the

10 10 data analysis system, along with a graph of test data picked peaks and a graph of smoothed test spectra data for a biological sample, and the input parameters specify display parameters.

15 33. A data analysis system of claim 28, wherein the data analysis system removes the residual baseline from the test data by modeling the baseline of the mass spectrometer data with a quadratic equation specified by the input parameters.

34. A data analysis system of claim 33, wherein the input parameters specify a range of data over which the baseline will be modeled.

20 35. A data analysis system of claim 34, wherein the baseline is modeled over a peak free region specified by the input parameters.

36. A data analysis system of claim 35, wherein the picked peaks graph represents all peaks in the mass spectrometer output that have a height that exceeds the residual baseline corrected data.

25 37. A data analysis system of claim 36, wherein the data analysis system validates a peak after comparing a probability density function for the peak free region with a probability density function for a fitted peak if the comparison shows that the respective probability density functions overlap by a predetermined amount.

38. A method for high throughput processing of biological samples,

30 the method comprising:
transporting a reaction vessel along a process line having a processing station that performs a mass spectrometer test procedure on one

or more biological samples contained in the reaction vessel;
providing the reaction vessel to the mass spectrometer and performing
the mass spectrometer test; and
continuously providing reaction vessels to the mass spectrometer and
5 receiving test results of the mass spectrometer and automatically
processing the test results to make a determination regarding a
characteristic of the biological samples in the reaction vessel,
wherein the characteristic is the biological sample genotype.

39. A method of claim 38, wherein the reaction vessel comprises a
10 multiple-well sample tray or solid support

40. A method of claim 38 or 39, wherein the step of continuously
providing reaction vessels to the mass spectrometer comprises automatically
transferring samples into the mass spectrometer for processing using a robotic
mass spectrometer interface.

15 41. A method of any of claims 38-40, wherein the step of receiving
test results comprises:

receiving test data from the mass spectrometer such that the test data for
a biological sample contains one or more peaks;
removing a residual baseline from the test data for a biological sample;
20 curve fitting each peak of the biological sample test data to
predetermined input parameters;
determining a probability that each peak of the biological sample test data
is a valid peak; and
making a data typing decision regarding the biological sample in
25 accordance with the determined valid peaks.

42. A method of any of claims 38-41, further including the step of
displaying exemplary test spectra for data types to be determined by the data
analysis system, along with a graph of test data picked peaks and a graph of
smoothed test spectra data for a biological sample.

30 43. A method of any of claims 38-42, wherein the data analysis
system receives test run input parameters that determine processing until a
different set of input parameters are received.

44. A method of claim 43, wherein the step of displaying comprises displaying exemplary test spectra for data types to be determined by the data analysis system, along with a graph of test data picked peaks and a graph of smoothed test spectra data for a biological sample, and the input parameters 5 specify display parameters.

45. A method of claim 41, wherein the step of removing the residual baseline from the test data by modeling the baseline of the mass spectrometer data with a quadratic equation specified by the input parameters.

46. A method of claim 45, wherein the input parameters specify a 10 range of data over which the baseline will be modeled.

47. A method of claim 46, wherein the baseline is modeled over a peak free region specified by the input parameters.

48. A method of claim 44, wherein the picked peaks graph represents all peaks in the mass spectrometer output that have a height that exceeds the 15 residual baseline corrected data.

49. A method of claim 48, wherein the data analysis system validates a peak after comparing a probability density function for the peak free region with a probability density function for a fitted peak if the comparison shows that the respective probability density functions overlap by a predetermined amount.

50. A method of claim 38-49, wherein the process line includes a 20 contamination-controlled environment and a non-sterile environment.

51. The method of claim 50, wherein the step of transporting includes automatically transporting samples between the two environments in a sterile taxicab.

52. The system of any of claims 13-15 that occupies two rooms, 25 wherein the components in each room are linked by an automated sample transporter.

53. The system of claim 52, wherein one room is a clean room.




FIG. 1




FIG. 2




FIG. 3

Nano-Plotter to Mass Spectrometer Sample Transfer




FIG. 4




FIG. 5




FIG. 6

Automatic Process Line Database analysis system	
From here you can:	
<input type="button" value="Go"/> Create a new Run	
<input type="button" value="Go"/> Copy an existing Run	You can copy a Run in order to re-run it on the API.
<input type="button" value="Go"/> Edit/View an existing Run	AMG1 <input type="button" value="►"/>
<input type="button" value="Go"/> Change status/Add comment	AMG1 <input type="button" value="►"/>
<input type="button" value="Go"/> View the history of a Run	AMG1 <input type="button" value="►"/>
<input type="button" value="Go"/> Create/Edit an Assay/Test	New <input type="button" value="►"/>

FIG. 7

7/7

[Home][Download][Runs][Assays]

Previous 100 Start At Find

AMCI Results

Row	Reaction_Details				Sample_Details				Assay_Details			
	PlateNo.	PlateID	Well	SampleNo.	SampleID	PlateNo.	PlateID	Well	AssayNo.	Name	Result	Spectrum
1	1	11S7872	A1	1	14C88	1	23R902	A1	1	AMG	MALE	11S7872_A1_sq
2	1	11S7872	A2	2	14C89	1	23R902	A2	1	AMG	MALE	11S7872_A2_sq
3	1	11S7872	A3	3	14C90	1	23R902	A3	1	AMG	FEMALE	11S7872_A3_sq
4	1	11S7872	A4	4	14C91	1	23R902	A4	1	AMG	FEMALE	11S7872_A4_sq
5	1	11S7872	A5	5	14C92	1	23R902	A5	1	AMG	MALE	11S7872_A5_sq
6	1	11S7872	A6	6	14C93	1	23R902	A6	1	AMG	FEMALE	11S7872_A6_sq
7	1	11S7872	A7	7	14C94	1	23R902	A7	1	AMG	MALE	11S7872_A7_sq
8	1	11S7872	A8	8	14C95	1	23R902	A8	1	AMG	FEMALE	11S7872_A8_sq
9	1	11S7872	A9	9	14C96	1	23R902	A9	1	AMG	MALE	11S7872_A9_sq
10	1	11S7872	A10	10	14C97	1	23R902	A10	1	AMG	MALE	11S7872_A10_sq
11	1	11S7872	A11	11	14C98	1	23R902	A11	1	AMG	FEMALE	11S7872_A11_sq
12	1	11S7872	A12	12	14C99	1	23R902	A12	1	AMG	FEMALE	11S7872_A12_sq
13	1	11S7872	B1	13	14C100	1	23R902	B1	1	AMG	MALE	11S7872_B1_sq
14	1	11S7872	B2	14	14C101	1	23R902	B2	1	AMG	FEMALE	11S7872_B2_sq
15	1	11S7872	B3	15	14C102	1	23R902	B3	1	AMG	MALE	11S7872_B3_sq
16	1	11S7872	B4	16	14C103	1	23R902	B4	1	AMG	FEMALE	11S7872_B4_sq
17	1	11S7872	B5	17	14C104	1	23R902	B5	1	AMG	MALE	11S7872_B5_sq

FIG. 8

SUBSTITUTE SHEET (RULE 26)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



**(43) International Publication Date
12 October 2000 (12.10.2000)**

PCT

**(10) International Publication Number
WO 00/60361 A3**

(51) International Patent Classification⁷: H01J 49/04, G01N 35/00

(21) International Application Number: PCT/US00/08111

(22) International Filing Date: 27 March 2000 (27.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/285,481 2 April 1999 (02.04.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/285,481 (CON)
Filed on 2 April 1999 (02.04.1999)

(71) Applicant (for all designated States except US): SE-QUENOM, INC. [US/US]; 11555 Sorrento Valley Road, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KÖSTER, Hubert [DE/US]; 8636-C Via Mallorca Drive, La Jolla, CA 92037 (US). YIP, Ping [US/US]; 3541 Copley Avenue, San Diego, CA 92116 (US). STEADMAN, Jhobe [US/US]; 11743 Aspen View Drive, San Diego, CA 92128 (US). REUTER, Dirk [DE/DE]; Walter-Gropius-Weg 7g, D-22844 Norderstedt (DE). MACDONALD, Richard [CA/US]; 6242 Snowbond Street, San Diego, CA 92120 (US).

(74) Agents: SEIDMAN, Stephanie, L. et al.; Heller Ehrman White & McAuliffe LLP, Suite 700, 4250 Executive Square, La Jolla, CA 92037 (US).


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— With international search report.

[Continued on next page]

(54) Title: AUTOMATED ANALYSERS



WO 00/60361 A3

(57) Abstract: A fully automated modular analytical system integrates instrumentation to permit analysis of biopolymer samples, such as nucleic acids, proteins, peptides and carbohydrates. The system integrates analytical methods of detection and analysis, such as mass spectrometry, radiolabeling, mass tags, chemical tags, fluorescence and chemiluminescence, with robotic technology and automated chemical reaction systems to provide a high-throughput, accurate automated system for high throughput analyses.



(88) Date of publication of the international search report:
8 February 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/08111

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 H01J49/04 G01N35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 H01J G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 498 545 A (VESTAL MARVIN L) 12 March 1996 (1996-03-12) column 3, line 10 - line 49; figures column 6, line 39 - line 52 column 7, line 15 - line 37 column 12, line 48 -column 13, line 16	1-4, 16-18, 28,29, 38-40
A	US 5 885 841 A (JULIAN JR RANDALL K ET AL) 23 March 1999 (1999-03-23) column 17, line 42 -column 18, line 17 column 19, line 15 -column 20, line 14 column 22, line 32 -column 23, line 37	13,50-52
Y	US 5 440 119 A (LABOWSKY MICHAEL J) 8 August 1995 (1995-08-08) column 12, line 33 - line 55; figures	5,6
A	----- -----	7-12
	----- -----	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

30 October 2000

Date of mailing of the international search report

13. 11. 00

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax. (+31-70) 340-3016

Authorized officer

Hocquet, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/08111

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 453 613 A (GRAY ZACHARY A ET AL) 26 September 1995 (1995-09-26) column 2, line 52 - line 59 ---	9
A	EP 0 596 205 A (HEWLETT PACKARD CO) 11 May 1994 (1994-05-11) page 2, line 10 - line 28 page 7, line 49 -page 8, line 9; figures page 16, line 1 - line 28 ---	1-13, 16-26, 28-52
A	WO 98 20166 A (DEN BOOM DIRK VAN ;JURINK CHRISTIAN (DE); HIGGINS G SCOTT (DE); L) 14 May 1998 (1998-05-14) cited in the application page 219, line 6 -page 221, line 22 ---	1-13, 16-26, 28-53
A,P	TAMMEN H ET AL: "Proteolytic cleavage of glucagon-like peptide-1 by pancreatic beta cells and by fetal calf serum analyzed by mass spectrometry" JOURNAL OF CHROMATOGRAPHY A,NL,ELSEVIER SCIENCE, vol. 852, no. 1, 6 August 1999 (1999-08-06), pages 285-295, XP004176692 ISSN: 0021-9673 paragraph '02.4! - paragraph '02.5! ---	5-12
A	SENKO M W ET AL: "Automated Assignment of Charge States from Resolved Isotopic Peaks for Multiply Charged Ions" JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY,US,ELSEVIER SCIENCE INC., NEW YORK, NY, vol. 6, no. 1, January 1995 (1995-01), pages 52-56, XP004195442 ISSN: 1044-0305 page 53, column 2, paragraph 3 ---	5-12
A	THOMPSON J N: "FITTING ROBOTS WITH WHITE COATS" CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 31, no. 3, 1 February 1996 (1996-02-01), pages 173-193, XP000584435 ISSN: 0169-7439 page 177, paragraph 313; figures 2,3 page 178, paragraph 43 -page 181, paragraph 4422 ---	13
Y	--- -/-	14,15

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/08111

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 15407 A (RUGGERI GUIDO ; STANGONI LORENZO (IT)) 5 August 1993 (1993-08-05) page 14, line 15 - line 23 page 16, line 15 -page 17, line 3 page 17, line 20 -page 18, line 5; figures page 18, line 28 -page 19, line 9 ---	14
Y	US 4 826 360 A (IWASAWA YOSHIYUKI ET AL) 2 May 1989 (1989-05-02)	15
A	column 2, line 14 - line 41 column 3, line 60 -column 4, line 31; figure 3 column 8, line 58 - line 60; figure 14 ---	27
A	FR 2 749 662 A (ELF AQUITAINE) 12 December 1997 (1997-12-12) page 4, line 21 - line 26 page 9, line 6 -page 10, line 5; figure 1 ---	14
A	HINTON E R ET AL: "THE APPLICATION OF ROBOTICS TO FLUOROMETRIC AND ISOTOPIC ANALYSES OF URANIUM" LABORATORY AUTOMATION & INFORMATION MANAGEMENT, NL, ELSEVIER SCIENCE PUBLISHERS BV., AMSTERDAM, vol. 21, no. 2/03, 1 December 1993 (1993-12-01), pages 223-227, XP000413295 ISSN: 1381-141X figure 2 ---	14
A	US 4 851 018 A (LAZZARI JEAN-PIERRE ET AL) 25 July 1989 (1989-07-25) column 1, line 13 -column 2, line 13 column 2, line 59 -column 3, line 18; figures column 9, line 30 - line 64; figure 6 ---	14,15

INTERNATIONAL SEARCH REPORT

national application No.
PCT/US 00/08111

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-13,16-26,28-52

automated system comprising a mass spectrometer and data analysing system processing the data of the mass spectrometer

2. Claims: 14-15,27 depending of 16

automated system comprising a contamination controlled environment and a non sterile environment each containing one or more processing stations, and a transport between the two environments.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte	onal Application No
PCT/US 00/08111	

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5498545	A	12-03-1996	AU 2960895 A DE 69508585 D DE 69508585 T EP 0771470 A JP 10513546 T WO 9603768 A		22-02-1996 29-04-1999 18-11-1999 07-05-1997 22-12-1998 08-02-1996
US 5885841	A	23-03-1999	NONE		
US 5440119	A	08-08-1995	US 5300771 A US 5635713 A		05-04-1994 03-06-1997
US 5453613	A	26-09-1995	EP 0708475 A JP 8128991 A		24-04-1996 21-05-1996
EP 0596205	A	11-05-1994	JP 6222830 A		12-08-1994
WO 9820166	A	14-05-1998	US 5900481 A US 6074823 A US 6024925 A AU 5106998 A DE 19782095 T EP 0954612 A NO 992168 A AU 5247298 A DE 19782097 T EP 0937097 A NO 992167 A WO 9820019 A AU 5198098 A DE 19782096 T DE 29724251 U DE 29724252 U EP 0937096 A NO 992169 A WO 9820020 A		04-05-1999 13-06-2000 15-02-2000 29-05-1998 23-03-2000 10-11-1999 06-07-1999 29-05-1998 14-10-1999 25-08-1999 05-07-1999 14-05-1998 29-05-1998 23-03-2000 17-08-2000 17-08-2000 25-08-1999 06-07-1999 14-05-1998
WO 9315407	A	05-08-1993	IT 1260447 B		09-04-1996
US 4826360	A	02-05-1989	JP 62209817 A JP 62222924 A JP 62222925 A CA 1271271 A EP 0239266 A		16-09-1987 30-09-1987 30-09-1987 03-07-1990 30-09-1987
FR 2749662	A	12-12-1997	WO 9747974 A		18-12-1997
US 4851018	A	25-07-1989	FR 2607406 A FR 2620049 A DE 3771464 D EP 0273791 A JP 63150545 A FR 2620049 B		03-06-1988 10-03-1989 22-08-1991 06-07-1988 23-06-1988 24-11-1989